Mostrar el registro sencillo del ítem
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: The authors' reply
dc.contributor.author | Bernal T. | |
dc.contributor.author | Martínez-Camblor P. | |
dc.contributor.author | Sánchez-García J. | |
dc.contributor.author | Sanz G. | |
dc.date.accessioned | 2020-09-02T22:13:07Z | |
dc.date.available | 2020-09-02T22:13:07Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1038/leu.2015.339 | |
dc.identifier.citation | 30, 3, 740-741 | |
dc.identifier.issn | 08876924 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/3739 | |
dc.description | [No abstract available] | |
dc.language.iso | en | |
dc.publisher | Nature Publishing Group | |
dc.title | Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: The authors' reply | |
dc.type | Letter |